LeMaitre Vascular, Inc.
LMATHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jun 1, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, LeMaitre Vascular, Inc. focuses on Medical Instruments & Supplies services and products. LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The $2.16B market capitalization puts LMAT squarely in mid-cap range for its industry. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services.
Market Cap
$2.16B
Beta
0.60
P/E (TTM)
34.80
P/E (Fwd)
29.07
EPS (TTM)
$2.72
EPS (Fwd)
$3.26
ROE
16.6%
ROA
7.2%
Cash
$367.2M
Total Debt
$189.8M
Free CF
$53.3M
52W Change
17.7%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $367.2M in cash comfortably exceeding the $189.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $53.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 16.6% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $161.7M (2022) to $249.6M (2025), reflecting a 54% increase over the period.
With a beta below 0.7, LeMaitre Vascular, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for LeMaitre Vascular, Inc. and its sector.